Analyst coverage

The analysts listed below are following Vernalis. Please note that any opinions, estimates or forecasts regarding Vernalis's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vernalis or its management. Vernalis does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Vernalis accepts no responsibility for the views of these or any other analysts.

 

Canaccord Genuity Limited (Nominated Advisor and Broker)  Howard Miller
Shore Capital (Joint Broker) Tara Raveendran
Edison Investment Research Lala Gregorek
N+1 Singer Jens Lindqvist
Stifel Max Herrmann
RX Securities Samir Devani
Panmure Gordon Julie Simmonds
Cantor Fitzgerald Brian White



Latest News

Unaudited Interim Results for the six months ended 31 December 2016

Vernalis plc (LSE: VER) today announces its unaudited consolidated results for the six month period ended 31 December 2016. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch